(Q44499920)

3 December 2017

HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer (English)

1 reference

3 December 2017

1 reference

Fabian Benencia

1

1 reference

3 December 2017

Maria C Courrèges

2

1 reference

3 December 2017

José R Conejo-García

3

1 reference

3 December 2017

Alisha Mohamed-Hadley

4

1 reference

3 December 2017

Lin Zhang

5

1 reference

3 December 2017

Ronald J Buckanovich

6

1 reference

3 December 2017

Richard Carroll

7

1 reference

3 December 2017

Nigel Fraser

8

1 reference

3 December 2017

George Coukos

9

1 reference

3 December 2017

31 May 2005

1 reference

3 December 2017

14

1 reference

based on heuristic

inferred from page(s)

published in

Molecular Therapy

1 reference

3 December 2017

12

1 reference

3 December 2017

789-802

1 reference

3 December 2017

5

1 reference

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

3 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

The biology of chemokines and their receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

The role of chemokine receptors in primary, effector, and memory immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

IP-10 and Mig facilitate accumulation of T cells in the virus-infected liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Mouse pre-immunocytes as non-proliferating multipotent precursors of macrophages, interferon-producing cells, CD8alpha(+) and CD8alpha(-) dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

The nature of the principal type 1 interferon-producing cells in human blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2005.03.026

10.1016/J.YMTHE.2005.03.026

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference